As recently reported by BloodThinnerHelp.com, the new federal MDL for Xarelto, and a new Philadelphia based Mass Torts Group have been established to coordinate pretrial discovery and administration of the litigation in lawsuits where Janssen (a subsidiary of Johnson & Johnson) and Bayer AG are facing allegations that the blood thinner Xarelto has caused serious injuries and death due to uncontrollable bleeding. A new federal lawsuit was filed in Louisiana this week as part of the Xarelto MDL by the son of a man from Georgia who unfortunately passed away from internal bleeding complications.
To view the complaint, click the button below, and to review summaries of all lawsuits filed in the Xarelto litigation, click here.
Allegations: Did Xarelto Cause Uncontrollable Bleeding That Lead To Untimely Death Of Plaintiff?
On March 20, 2015, the son of a man from Georgia filed this Xarelto lawsuit against the manufacturers of the blood thinner in the United States District Court For The Eastern District of Louisiana. The son, a resident of Tennessee, alleged that his father died from uncontrollable bleeding which he believes was caused by Xarelto. The case was filed under case number: 2:15-cv-00886.
According to the complaint, the plaintiff’s father was prescribed Xarelto to treat his atrial fibrillation, a heart condition for which Xarelto was approved by the FDA, in November 2012. In March 2013, the plaintiff’s father died because of an internal bleeding event, which the complaint outlined would not have happened if they knew about the risks prior to taking the drug, because the plaintiff’s father would have taken a safer alternative.
The complaint alleged that the manufacturers of Xarelto concealed knowledge that the blood thinner could cause irreversible life threatening internal bleeding and that the defendants didn’t adequately warn consumers and the medical community about the irreversible nature of the drug. The complaint continued that the defendants did not equip the medical community with advise on how to stabilize a patient should a bleeding event occur.
What Is Atrial Fibrillation and How Did Xarelto Lead To This Man’s Death?
Atrial Fibrillation is a very common irregular heart beat suffered by more than 3 million people per year in the US (Source: National Heart, Lung, and Blood Institute). The arrhythmia can cause the hear to beat too slow, too fast, or just in an irregular fashion. It is caused by the two upper chambers of the heart contracting irregularly due to abnormal electrical signals. This results in blood pooling in the atria or upper chambers and not supplying blood to the lower chambers to be pumped around the body. This pooling can lead to a higher risk of blood clotting and stroke. As a result, the medical community prescribe blood thinners such as: Xarelto (Rivaroxaban), Eliquis (Apixaban), Pradaxa (Dabigatran), and Lixiana (Edoxaban).
In this lawsuit, the plaintiff’s father suffered from “Afib” and was prescribed the blood thinner Xarelto to thin his blood and reduce the risk of clotting and stroke. Unfortunately, the plaintiff’s father’s ingestion of Xarelto may have contributed to his death as internal bleeding could not be stopped by his doctors.
What Is The Status Of Xarelto Lawsuits?
As of the time of filing of this lawsuit, the federal MDL for Xarelto had over 300 lawsuits transferred for administration of the cases. Based on the numbers of prescriptions issued for Xarelto, and the incidents of internal bleeding events, we believe there will be thousands more lawsuits filed in the coming year. Xarelto is from a class of blood thinners that all have the same problem of not having an antidote. Pradaxa, a blood thinner from this class has already settled 4,000 cases for $650 million. While there have been no trials or settlements to date, we will bring you news of such developments as they occur.